medigraphic.com

2005, Number 6

<< Back Next >>

Rev Fac Med UNAM 2005; 48 (6)

Beta-blockers in chronic pneumopathy

Pérez RFR

Language: Spanish
References: 30
Page: 236-241
PDF size: 54.75 Kb.


ABSTRACT

Antecedents: The use of the beta-blockers in the patients with chronic lung disease has been feared by the adverse effects on the airway, without taking in consideration the pharmacology of this type of drugs. Objective: To revise the pharmacological characteristics of the beta-blockers systematically, as well as their uses, contraindications, and adverse effects, making emphasis in the effects on the breathing function of the patients with chronic obstructive pulmonary disease (COPD) and/or asthma, associated to ischemic heart disease, systemic arterial hypertension, congestive heart failure (ICC) and others. Source of data and selection of studies: The search was carried out in the database Medline from 1985 until September of 2004, identifying studies on patients with heart and lung disease, and the contraindications for betablockers use, as well as revisions of all the pharmacological aspects of these drugs. Thirty one original articles, goal-analysis and revisions were identified on betablockers, heart disease and COPD or asthma. Synthesis of the data: Betablockers have been considered one of the most important advances in clinical pharmacology; their multiple uses due to the action on several types of receivers rebound in the function of some of those organs. Cardiovascular diseases are closely associated to chronic lung disease so diverse studies have evaluated the repercussion of beta-blockers of breathing. Conclusions: Although in the medical literature it has been considered traditionally that beta-blockers are contrain dicated on patients with chronic neumopathies specifically in COPD and asthma, the revision of the effects on the receivers, makes almost obvious the conclusion that the use of the cardioselective beta-blockers, can be used with surveillance without adverse effects as the bronchoconstriction. It is necessary to insist that non cardioselective beta-blockers should be considered contraindicated.


REFERENCES

  1. Frishman WH, Alwarshetty M. b-Adrenergic blockers in systemic hypertension. Pharmacokinetic considerations related to the current Guidelines. Clin Pharmacokinet 2002; 20: 505-516.

  2. López-Sendón J, Swedberg K, McMuray J et al. Expert consensus document on b-adrenergic receptor blockers. The task force on beta-blockers of the European Society of Cardiology. Eur Heart J 2004; 25: 1341-1357.

  3. Pancu D, Lee DC. b-blocker use in the emergency department in patients with acute myocardial infarction undergoing primary angioplasty. J Emerg Med 2003; 24: 379-382.

  4. Faller M, Quoix E, Popin E et al. Migratory pulmonary infiltrates in a patient treated with sotalol. Eur Respir J 1997; 10: 2159-2162.

  5. Tattersfield AE. Respiratory function in the elderly and the effects of beta blockade. Cardiovasc Drugs Ther 1991; 4 supp 6: 1229-1232.

  6. Sirak TE, Jelic S, Le Jemtel TH. Therapeutic update: Non-selective beta and alpha-adrenergic blockade in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure. J Am Coll Cardiol 2004; 44: 497-502.

  7. Chen J, Radford MJ, Wang Y et al. Effectivenes of beta-blocker therapy after acute myocardial infarction in elderly patients with chronic obstructive pulmonary disease or asthma. J Am Coll Cardiol 2001; 37: 1950-1956.

  8. Hedner J, Ullman A, Lemne C et al. Effects of dilevalol, a beta-adrenoceptor antagonist with intrinsic sympathetic activity in asthmatic patients. Pulm Pharmacol 1989; 2: 155-159.

  9. Salpeter SR Ormiston TM, Salpeter EE et al. Cardioselective beta-blockers for chronic obstructive pulmonary disease: a meta-analysis. Resp Med 2003; 97: 1094-1101.

  10. Miki A, Tanaka Y, Ohtani H et al. Betaxolol-induced deterioration of asthma and a pharmacodynamic analysis based on beta-receptor occupancy. Int J Clin Pharmacol Ther 2003; 41: 358-364.

  11. Camsari A, Arikan S, Avan C et al. Metoprolol, a beta-1 selective blocker, can be used safely in coronary artery disease patients with chronic obstructive pulmonary disease. Heart Vessels 2003; 18: 188-192.

  12. Dorow P, Talhofer S, Bethge H et al. Long-term treatment of angina pectoris with bisoprolol or atenolol in patients with chronic obstructive bronchitis: a randomized, double-blind crossover study. J Cardiovasc Pharmacol 1990; 16 supp 5: S36-S44.

  13. Dorow P, Bethge H, Tonnesmann U. Effects of single oral doses of bisoprolol and atenolol on airway function in nonasthmatic chronic lung disease and angina pectoris. Eur J Clin Pharmacol 1986; 31: 143-147.

  14. Fogari R, Zoppi A, Tettamanti F et al. Comparative effects of celiprolol, propranolol, oxprenolol, and atenolol on respiratory function in hypertensive patients with chronic obstructive lung disease. Cardiovasc Drugs Ther 1990; 4: 1145-1149.

  15. van Zyl AI, Jennings AA, Baetman ED et al. Comparison of respiratory effects of two cardioselective beta-blockers, celiprolol and atenolol, in asthmatics with mild to moderate hypertension. Chest 1989; 95: 209-213.

  16. Kotlyar E, Keogh AM, Macdonald PS et al. Tolerability of carvedilol in patients with heart failure and concomitant chronic obstructive pulmonary disease or asthma. J Heart Lung Transplant 2002; 21:1290-1295.

  17. Chodosh S, Tuck J, Blauscci DJ. The effects of dilevalol, metoprolol, and placebo on ventilatory function in asthmatics. J Cardiovasc Pharmacol 1988; 11 supp 2: S18-S24.

  18. Kirwan JF, Nightingale JA, Bunce C et al. Do selective topical beta antagonists for glaucoma have respiratory side effects? Br J Ophthalmol 2004; 88: 196-198.

  19. Hugues FC, Matte JC, Le Jeunne C et al. Effects of beta-adrenoceptors blocking eye drops in patients with chronic bronchitis. Therapie 1992; 47: 211-215.

  20. Pujet JC, Dubreuil C, Fleury B et al. Effects of celiprolol, a cardioselective beta-blocker, on respiratory function. Eur Resp J 1992; 5: 196-200.

  21. Bruschi C, Casali L, Cerveri I et al. Effects of celiprolol on the bronchial reactivity in asthma. Am J Cardiol 1988; 61: 53C-54C.

  22. Cazzola M, Noschese P, D’Amato M et al. Comparison of the effects of single oral doses of nebivolol and celiprolol on airways in patients with mild asthma. Chest 2000; 118: 1322-1326.

  23. Bekker A, Sorour K, Miller S. The use of cardioselective beta-blockers in a patient with idiopathic hypertrophic subaortic stenosis and chronic obstructive pulmonary disease. J Clin Anesth 2002; 14: 589-591.

  24. Gold MR, Dec GW, Cocca-Spofford D et al. Esmolol and ventilatory function in cardiac patients with COPD. Chest 1991; 100: 1215-1218.

  25. Shepard D, DiStefano S, Byrd RC et al. Effects of esmolol on airway function in patients with asthma. J Clin Pharmacol 1986; 26: 169-174.

  26. Cazzola M, Noschese P, Amato G et al. The pharmacologic treatment of uncomplicated arterial hypertension in patients with airway dysfunction. Chest 2002; 121: 230-241.

  27. Krane NK, Wallin JD. Managing the elderly patient with both hypertension and pulmonary disease. Geriatrics 1987; 42: 45-49, 52.

  28. Shiga T, Wakaumi M, Yajima T et al. Beta-blocker therapy combined with low-dose pimobendan in patients with idiopathic dilated cardiomyopathy and chronic obstructive pulmonary disease: report on two cases. Cardiovasc Drugs Ther 2002; 16: 259-63.

  29. Salpeter SR, Ormiston TM, Salpeter EE. Cardioselective beta blockers in patients with reactive airway disease: a meta-analysis. Ann Intern Med 2002; 137: 715-725.

  30. Sackner-Bernstein JD. Practical guidelines to optimize effectiveness of b-blockade in patients postinfarction and in those with chronic heart failure. Am J Cardiol 2004; 93(suppl): 69B-73B.




2020     |     www.medigraphic.com